Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

DNA-interactive agents

Autor: L, Kelland

Publikováno v: IDrugs : the investigational drugs journal. 1(4)

Currently, approximately 40 drugs are registered for the chemotherapeutic treatment of cancer, the vast majority of which either interact directly with DNA (eg, alkylating, methylating, platinating agents, topoisomerase inhibitors), or affect DNA syn

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::ab0452f2775007d7697b93760d7e0975
https://pubmed.ncbi.nlm.nih.gov/18465568

NCI-EORTC--10th Symposium--new approaches and cellular targets. 16-19 June 1998, Amsterdam, The Netherlands

Autor: L, Kelland

Publikováno v: IDrugs : the investigational drugs journal. 1(4)

This meeting was the tenth in a series dating back 20 years. The symposium provided a forum for the presentation and discussion of recent results on the preclinical and early clinical R and D of new anticancer agents. Reflecting the current opinions

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::6334a0079937dacc24777772201c1657
https://pubmed.ncbi.nlm.nih.gov/18465566

Resource allocation for chronic stable angina: a systematic review of effectiveness, costs and cost-effectiveness of alternative interventions

Autor: Martin Buxton, D R Holdright, M Petticrew, Rachel Elliott, Mark Sculpher, J L Kelland

Publikováno v: Health Technology Assessment, Vol 2, Iss 10 (1998)
Scopus-Elsevier
Sculpher, M J, Petticrew, M, Kelland, J L, Elliott, R A, Holdright, D R & Buxton, M J 1998, ' Resource allocation for chronic stable angina : a systematic review of effectiveness, costs and cost-effectiveness of alternative interventions ', Health Technology Assessment, vol. 2, no. 10, pp. 1-176 . https://doi.org/10.3310/hta2100

Objectives: To update earlier reviews of the effectiveness of treatment for chronic stable angina and to include assessment of medical therapy and of newer adjunctive technologies such as coronary stents broader assessment of patient benefits conside

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb4d01d3e57d22f20f202b36aec9b9da
https://doaj.org/article/f92c1d107f4740e29e2a836f5a8b0f74